Spinal Muscular Atrophy: Four trials to watch over the next 12 months
With just five treatments available for spinal muscular atrophy, how are clinical trials trying to improve patients’ quality of life?
14 August 2023
14 August 2023
With just five treatments available for spinal muscular atrophy, how are clinical trials trying to improve patients’ quality of life?
A statistically significant improvement in PFS was observed in SKB264 group against control group receiving standardised chemotherapy.
The experts recommended that the study should continue further with a longer follow-up time and without a placebo group.
The study was conducted at the First Bethune Hospital of Jilin University.
The latest tag adds to three fast track designations for Reqorsa, with the company initiating a Phase I/II trial in Q4 2023.
The first-in-human study will determine the recommended Phase II dose.
vTv plans to initiate a Phase III study with an FDA-recommended primary endpoint by the end of 2023.
Citius is approaching the end of its Phase III trial after meeting all 92 events, pending an independent review.
Outsourcing in Clinical Trials Southern California Conference 2023 will be returning to Hyatt Regency La Jolla at Aventine, USA on the 26th-27th September 2023! Focusing on interactive discussions to provide insight into the current major operational issues with running clinical trials in the coming years.
Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.
Give your business an edge with our leading industry insights.